BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 26615127)

  • 1. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fibroblast growth factor receptor pathway in breast cancer.
    Criscitiello C; Esposito A; De Placido S; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR-targeted therapeutics for the treatment of breast cancer.
    De Luca A; Frezzetti D; Gallo M; Normanno N
    Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the fibroblast growth factor receptor family in cancer.
    Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
    Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
    André F; Cortés J
    Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
    Brooks AN; Kilgour E; Smith PD
    Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
    Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
    Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of fibroblast growth factor receptors in cancer.
    Liang G; Chen G; Wei X; Zhao Y; Li X
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
    Helsten T; Schwaederle M; Kurzrock R
    Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
    Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
    Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and challenges in targeting FGFR signalling in cancer.
    Babina IS; Turner NC
    Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?
    Bedussi F; Bottini A; Memo M; Fox SB; Sigala S; Generali D
    Expert Opin Ther Targets; 2014 Jun; 18(6):665-78. PubMed ID: 24833241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
    Dianat-Moghadam H; Teimoori-Toolabi L
    Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.